#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Real cost of chronic myeloid leukemia treatment with nonmyeloablative hematopoietic stem cell transplantation and comparison with cost of hypothetical imatinib treatment. What shall be considered in the cases of extremely costly medical procedures?


Authors: J. Mayer;  Y. Brychtová;  M. Doubek;  M. Krejčí;  J. Vorlíček
Authors‘ workplace: Interní hematoonkologická klinika FN Brno - Bohunice
Published in: Transfuze Hematol. dnes,12, 2006, No. 1, p. 6-13.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

In chronic myeloid leukemia (CML), allogeneic hematopoietic stem cell transplantation is still considered as the only curative procedure. However, older reports unanimously showed the high frequency of transplant-related complications and deaths. In recent years, 2 new treatments emerged: nonmyeloablative hematopoietic stem cell transplantation and imatinib. The first one is a modification of well-known transplant principles with intention to lower their side effects. Imatinib, a completely new drug, has been discovered by harnessing the newest knowledge of CML molecular pathogenesis. However, imatinib is not able to satisfactorily eradicate all malignant cells. Both treatments options, albeit very different concerning the mechanism of action and side effects, have actually one common feature – high cost. In this work, the real transplant cost (1st chronic phase CML, conditioning with busulfan + fludarabine + ATG) was compared with hypothetical imatinib treatment (400 mg/day) in the same patients; the lengths of imatinib treatment corresponded to the follow-ups upon the transplantation (3-82 months). Two transplanted patients died from intractable GvHD. The total cost of transplantation treatment of all patients is 45 991 020 Kč (median: 2 197 948 Kč; mean: 2 299 551 Kč). The main cost burdens were hospitalizations, laboratory examinations, and outpatient drug treatment. The total cost of hypothetical imatinib treatment would be 58 629 488 Kč (median: 2 235 844 Kč; mean 2 931 474 Kč). The main cost burden was imatinib itself. Imatinib treatment would be especially high in patients who would have longer follow-up. It seems that transplantation treatment starts to be less expensive than imatinib after 2 years of follow-up. This work cannot answer the complex question of indication of either treatment option. It showed, however, that treatment cost is a very important parameter in the decision algorithm. The authors mean that in newly diagnosed 1st chronic phase CML patients with an HLA-identical family donor, the hematopoietic stem cell transplantation with a nonmyeloablative conditioning (busulfan + fludarabine + ATG) is still a very valid option.

Key words:
imatinib, chronic myeloid leukemia, bone marrow/peripheral blood stem cell transplantation, pharmacoeconomics


Labels
Haematology Internal medicine Clinical oncology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#